Is Zenas BioPharma, Inc. Common Stock (ZBIO) overvalued? · rev $5.0M
Zenas BioPharma, Inc. Common Stock (ZBIO) is a biotechnology company listed on US.
This page asks whether Zenas BioPharma, Inc. Common Stock (ZBIO) looks expensive on cached numbers — not a short thesis.
Latest reported ZBIO revenue for 2024-12-31 was $5.0M. Net income was -$157.0M. Revenue was down 90.0% from 2023-12-31 to 2024-12-31. ZBIO currently screens at market cap $798.0M.
ZBIO currently screens at market cap $798.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ZBIO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ZBIO stock page for the full model, not this heading.
Not investment advice.